Boyle Miriam L, Ruth-Sahd Lisa A, Zhou Zehao
Lisa Ruth-Sahd is an associate professor of nursing at York College of Pennsylvania. She is also a nurse extern coordinator at Lancaster General Hospital, Lancaster, Pennsylvania.Zehao Zhou is an assistant professor and information services librarian of Schmidt Library, York College of Pennsylvania.
Crit Care Nurse. 2015 Apr;35(2):51-64; quiz 65. doi: 10.4037/ccn2015356.
The prevalence of recurrent or refractory Clostridium difficile infection has been steadily increasing since 2000. Consequently, alternative treatments to the standard antibiotic therapies are now being considered. One alternative treatment is fecal microbiota transplant. Although fecal microbiota transplant is relatively new--and not appealing to most people--it has been around for many years and has great promise as an inexpensive, safe, and efficient treatment of refractory and recurrent C difficile infection. With a better understanding of the intricacies of the colonic microbiome and its role in colonic physiology and pathophysiology, critical care nurses will recognize that fecal microbiota transplant has the potential to become the standard of care for treatment of recurrent or refractory C difficile infection. The American College of Gastroenterology and the Infectious Diseases Society of America provide the latest treatment guidelines for care of patients with these clostridial infections.
自2000年以来，复发性或难治性艰难梭菌感染的患病率一直在稳步上升。因此，目前正在考虑采用标准抗生素疗法以外的替代治疗方法。一种替代治疗方法是粪便微生物群移植。尽管粪便微生物群移植相对较新——而且对大多数人来说缺乏吸引力——但它已经存在多年，作为一种治疗难治性和复发性艰难梭菌感染的廉价、安全且有效的方法，具有很大的前景。随着对结肠微生物组的复杂性及其在结肠生理和病理生理学中的作用有了更深入的了解，重症护理护士将认识到粪便微生物群移植有可能成为复发性或难治性艰难梭菌感染治疗的护理标准。美国胃肠病学会和美国传染病学会提供了这些梭菌感染患者护理的最新治疗指南。
